Site Sponsors
  • Oxford Instruments Nanoanalysis - X-Max Large Area Analytical EDS SDD
  • Park Systems - Manufacturer of a complete range of AFM solutions
  • Strem Chemicals - Nanomaterials for R&D
Posted in | Bionanotechnology

Bruker and KIESTRA to Co-Market Technologies for Microbiology Routine Laboratories

Published on April 12, 2010 at 5:13 AM

Prior to the 20th Annual Meeting of the European Society of Clinical Microbiology and Infectious Diseases on April 10-13, 2010 in Vienna, Bruker Daltonics and KIESTRA Lab Automation announce an expanded partnership covering co-marketing and cross-selling of their respective technologies for microbiology routine laboratories, as well as a joint research and development program for interfacing their technologies.

Bruker's MALDI Biotyper with KIESTRA's MalditofA lab automation system

In recent years, Bruker and KIESTRA Lab Automation have worked with a number of customers applying both technologies in their laboratories. Together with the Academical Medical Center (Amsterdam), the Jeroen Bosch Hospital (Den Bosch), Leiden University Medical Center (Leiden) and Streeklab Haarlem (Haarlem), both companies applied for the prestigious European Research Initiative EUREKA. Typically, EUREKA R&D is lead by industry and is focused on significant new customer requirements. In March 2010, the participating project partners ranked at third position of the EUREKA tender for their joint 24/7 Bacteriology Identification & Sensitivity System (BISS) project. In addition to integration of both technologies, a goal of the BISS project is to enable unattended 24/7 operation for bacterial identification.

Mr. Jetze Botma, Chief Executive Officer at KIESTRA Lab Automation, stated: "It is remarkable to see how relatively new players in the microbiology market have changed the competitive landscape in the last couple of years. The trends of consolidation of laboratories and of centralizing microbiology laboratory services will further increase the demand for professional automation solutions. In addition, an early identification by the MALDI Biotyper in many cases can already initiate a germ-specific therapy, which leads to a significant increase in laboratory and hospital efficacy. The effective combination of both technologies will help to ease the burden on the healthcare system."

Dr. Wolfgang Pusch, Vice President for Clinical Research Solutions & IVD at Bruker Daltonics, added: "This strategic partnership with KIESTRA Lab Automation is an excellent match for Bruker. We are two leading suppliers offering innovative technologies for the microbiology market, in laboratory automation and in molecular microbial ID. Each of our technologies alone has been quite successful already, and in combination they could change the way microbiology is performed in many routine labs. KIESTRA´s technology brings the same level of automation into the microbiology lab that was introduced in clinical chemistry 15 years ago. Moreover, the MALDI Biotyper reduces the identification turnaround time for patient samples significantly. Both technologies integrated together will help microbiology laboratories to perform their important tasks faster and better, despite a predicted shortage in experienced laboratory staff."

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit